Literature DB >> 11090077

Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways.

M Mizuki1, R Fenski, H Halfter, I Matsumura, R Schmidt, C Müller, W Grüning, K Kratz-Albers, S Serve, C Steur, T Büchner, J Kienast, Y Kanakura, W E Berdel, H Serve.   

Abstract

Somatic mutations of the receptor tyrosine kinase Flt3 consisting of internal tandem duplications (ITD) occur in 20% of patients with acute myeloid leukemia. They are associated with a poor prognosis of the disease. In this study, we characterized the oncogenic potential and signaling properties of Flt3 mutations. We constructed chimeric molecules that consisted of the murine Flt3 backbone and a 510-base pair human Flt3 fragment, which contained either 4 different ITD mutants or the wild-type coding sequence. Flt3 isoforms containing ITD mutations (Flt3-ITD) induced factor-independent growth and resistance to radiation-induced apoptosis in 32D cells. Cells containing Flt3-ITD, but not those containing wild-type Flt3 (Flt3-WT), formed colonies in methylcellulose. Injection of 32D/Flt3-ITD induced rapid development of a leukemia-type disease in syngeneic mice. Flt3-ITD mutations exhibited constitutive autophosphorylation of the immature form of the Flt3 receptor. Analysis of the involved signal transduction pathways revealed that Flt3-ITD only slightly activated the MAP kinases Erk1 and 2 and the protein kinase B (Akt) in the absence of ligand and retained ligand-induced activation of these enzymes. However, Flt3-ITD led to strong factor-independent activation of STAT5. The relative importance of the STAT5 and Ras pathways for ITD-induced colony formation was assessed by transfection of dominant negative (dn) forms of these proteins: transfection of dnSTAT5 inhibited colony formation by 50%. Despite its weak constitutive activation by Flt3-ITD, dnRas also strongly inhibited Flt3-ITD-mediated colony formation. Taken together, Flt3-ITD mutations induce factor-independent growth and leukemogenesis of 32D cells that are mediated by the Ras and STAT5 pathways. (Blood. 2000;96:3907-3914)

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11090077

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  164 in total

1.  Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD.

Authors:  Jennifer L Rocnik; Rachel Okabe; Jin-Chen Yu; Benjamin H Lee; Neill Giese; David P Schenkein; D Gary Gilliland
Journal:  Blood       Date:  2006-04-20       Impact factor: 22.113

2.  Mutation of FLT3 gene in acute myeloid leukemia with normal cytogenetics and its association with clinical and immunophenotypic features.

Authors:  Pradeep S Chauhan; Bharat Bhushan; Ashwani K Mishra; Laishram C Singh; Sumita Saluja; Saurabh Verma; Dipendra K Gupta; Vishakha Mittal; Sumita Chaudhry; Sujala Kapur
Journal:  Med Oncol       Date:  2010-03-31       Impact factor: 3.064

3.  Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia.

Authors:  Derek L Stirewalt; Kenneth J Kopecky; Soheil Meshinchi; Julia H Engel; Era L Pogosova-Agadjanyan; Jeremy Linsley; Marilyn L Slovak; Cheryl L Willman; Jerald P Radich
Journal:  Blood       Date:  2005-12-20       Impact factor: 22.113

4.  Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade.

Authors:  Noria Harir; Cédric Boudot; Katrin Friedbichler; Karoline Sonneck; Rudin Kondo; Séverine Martin-Lannerée; Lukas Kenner; Marc Kerenyi; Saliha Yahiaoui; Valérie Gouilleux-Gruart; Jean Gondry; Laurence Bénit; Isabelle Dusanter-Fourt; Kaïss Lassoued; Peter Valent; Richard Moriggl; Fabrice Gouilleux
Journal:  Blood       Date:  2008-06-25       Impact factor: 22.113

5.  Transcriptome dynamics during human erythroid differentiation and development.

Authors:  Yadong Yang; Hai Wang; Kai-Hsin Chang; Hongzhu Qu; Zhaojun Zhang; Qian Xiong; Heyuan Qi; Peng Cui; Qiang Lin; Xiuyan Ruan; Yaran Yang; Yajuan Li; Chang Shu; Quanzhen Li; Edward K Wakeland; Jiangwei Yan; Songnian Hu; Xiangdong Fang
Journal:  Genomics       Date:  2013-10-08       Impact factor: 5.736

6.  Mechanisms of apoptosis induction by simultaneous inhibition of PI3K and FLT3-ITD in AML cells in the hypoxic bone marrow microenvironment.

Authors:  Linhua Jin; Yoko Tabe; Hongbo Lu; Gautam Borthakur; Takashi Miida; Hagop Kantarjian; Michael Andreeff; Marina Konopleva
Journal:  Cancer Lett       Date:  2012-10-02       Impact factor: 8.679

7.  Uniform sensitivity of FLT3 activation loop mutants to the tyrosine kinase inhibitor midostaurin.

Authors:  Elly V Barry; Jennifer J Clark; Jan Cools; Johannes Roesel; D Gary Gilliland
Journal:  Blood       Date:  2007-09-07       Impact factor: 22.113

8.  NF-κB/STAT5/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia.

Authors:  D Gerloff; R Grundler; A A Wurm; D Bräuer-Hartmann; C Katzerke; J-U Hartmann; V Madan; C Müller-Tidow; J Duyster; D G Tenen; D Niederwieser; G Behre
Journal:  Leukemia       Date:  2014-08-05       Impact factor: 11.528

Review 9.  Potential role of sorafenib in the treatment of acute myeloid leukemia.

Authors:  Shahram Mori; Jorge Cortes; Hagop Kantarjian; Weiguo Zhang; Michael Andreef; Farhad Ravandi
Journal:  Leuk Lymphoma       Date:  2008-12

10.  Construction and application of an inducible system for homogenous expression levels in bulk cell lines.

Authors:  Jun Yu; Helena Müller; Sina Hehn; Steffen Koschmieder; Kai Schönig; Wolfgang E Berdel; Hubert Serve; Carsten Müller-Tidow
Journal:  PLoS One       Date:  2009-07-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.